Effects of morin on the pharmacokinetics of docetaxel in rats with 7,12-dimethylbenz[a]anthracene (DMBA)-induced mammary tumors

Archives of Pharmacal Research

Volumn 34, Issue 10, 2011, Pages 1729-1734

  Yang, Si H ^a   Lee, Joo H ^b   Lee, Dae Y ^c   Lee, Myung G ^d   Lyuk, Koon C ^e   Kim, So H ^f  

^a Dankook University   (South Korea)

^b Kyung Hee University   (South Korea)

^c Dong A Pharmaceutical Company   (South Korea)

^d The Catholic University of Korea   (South Korea)

^e Cranbrook Schools   (United States)

^f Gangneung Wonju National University   (South Korea)

Author keywords

CYP3A; DMBA induced mammary tumors; Docetaxel; Morin; P glycoprtein; Pharmacokinetics

Indexed keywords

DIMETHYLBENZ[A]ANTHRACENE; DOCETAXEL; GLYCOPROTEIN P; MORIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; BREAST TUMOR; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFECT; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTESTINE; LIQUID CHROMATOGRAPHY; LIVER METABOLISM; MEAN RESIDENCE TIME; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; RAT; TANDEM MASS SPECTROMETRY;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; FLAVONOIDS; HALF-LIFE; HUMANS; INJECTIONS, INTRAVENOUS; INTESTINES; LIVER; MAMMARY NEOPLASMS, EXPERIMENTAL; MASS SPECTROMETRY; P-GLYCOPROTEIN; RATS; TAXOIDS;

EID: 82055176071     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-011-1017-z     Document Type: Article

References (28)

1. S. D. Baker M. Zhao P. He M. A. Carducci J. Verweij A. Sparreboom 2004 Simultaneous analysis of docetaxel and the formulation vehicle polysorbate 80 in human plasma by liquid chromatography/tandem mass spectrometry Anal. Biochem. 324 276 284 14690692 10.1016/j.ab.2003.09.038 1:CAS:528:DC%2BD3sXhtVSjurrE (Pubitemid 38019018)
2. M. Ben Reguiga L. Bonhomme-Faivre R. Farinotti 2007 Bioavailability and tissue distribution of docetaxel, a Pglycoprotein substrate, are modified by interferon-alpha in rats J. Pharm. Pharmacol. 59 401 408 17331344 10.1211/jpp.59.3.0010 1:CAS:528:DC%2BD2sXjtleqtr4%3D (Pubitemid 47050905)
3. R. Bruno G. J. Sanderink 1993 Pharmacokinetics and metabolism of Taxotere (docetaxel) Cancer Surv. 17 305 313 7907950 1:CAS:528:DyaK2cXkt1Kju74%3D
4. W. L. Chiou 1978 Critical evaluation of the potential error in pharmacokinetic studies using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve J. Pharmacokinet. Biopharm. 6 539 546 731416 10.1007/BF01062108 1:CAS:528:DyaE1MXpslanuw%3D%3D
5. B. C. Choi J. S. Choi H. K. Han 2006 Altered pharmacokinetics of paclitaxel by the concomitant use of morin in rats Int. J. Pharm. 323 81 85 16806758 10.1016/j.ijpharm.2006.05.046 1:CAS:528:DC%2BD28XpvVOmtrg%3D (Pubitemid 44397361)
6. H. J. Choi J. S. Choi 2005 Effects of morin pretreatment on the pharmacokinetics of diltiazem and its major metabolite, desacetyldiltiazem in rats Arch. Pharm. Res. 28 970 976 16178425 10.1007/BF02973885 1:CAS:528:DC%2BD2MXhtVSktrfK
7. J. S. Choi Y. J. Piao K. W. Kang 2011 Effects of quercetin on the bioavailability of doxorubicin in rats: role of CYP3A4 and P-gp inhibition by quercetin Arch. Pharm. Res. 34 607 613 21544726 10.1007/s12272-011-0411-x 1:CAS:528:DC%2BC3MXls1CqsrY%3D
8. Y. H. Choi J. H. Suh J. H. Lee I. H. Cho M. G. Lee 2010 Effects of tesmilifene, a substrate of CYP3A and an inhibitor of P-glycoprotein, on the pharmacokinetics of intravenous and oral docetaxel in rats J. Pharm. Pharmcol. 62 1084 1088 10.1111/j.2042-7158.2010.01129.x 1:CAS:528:DC%2BC3cXhtVeis7bN
9. B. Davies T. Morris 1993 Physiological parameters in laboratory animals and humans Pharm. Res. 10 1093 1095 8378254 10.1023/A:1018943613122 1:STN:280:DyaK3szptFaqsg%3D%3D (Pubitemid 23211439)
10. K. C. Fendl S. J. Zimniski 1992 Role of tamoxifen in the induction of hormone-independent rat mammary tumors Cancer Res. 52 235 237 1727383 1:CAS:528:DyaK38XltFSrug%3D%3D
11. Gibaldi, M. and Perrier, D., Pharmacokinetics. 2nd ed. Marcel-Dekker, New York, (1982).
12. P. Hodek P. Trefil M. Stiborová 2002 Flavonoids-potent and versatile biologically active compounds interacting with cytochromes P450 Chem. Biol. Interact. 139 1 21 11803026 10.1016/S0009-2797(01)00285-X 1:CAS:528:DC%2BD38XmsFajtg%3D%3D (Pubitemid 34135994)
13. C. Huggins L. C. Grand F. P. Brillantes 1961 Mammary cancer induced by a single feeding of polymucular hydrocarbons, and its suppression Nature 189 204 207 13716610 10.1038/189204a0 1:CAS:528:DyaF3MXms1Wgtg%3D%3D
14. X. Li J. K. Yun J. S. Choi 2007 Effects of morin on the pharmacokinetics of etoposide in rats Biopharm. Drug Dispos. 28 151 156 17315145 10.1002/bdd.539 (Pubitemid 46730923)
15. Z. Lwin N. Leighl 2009 Economic evaluation of docetaxel for breast cancer Expert Opin. Pharmacother. 10 283 290 19236199 10.1517/14656560802653206 1:CAS:528:DC%2BD1MXntlOlsA%3D%3D
16. M. M. Malingré D. J. Richel J. H. Beijnen H. Rosing F. J. Koopman W. W. Ten Bokkel Huinink M. E. Schot J. H. Schellens 2001 Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel J. Clin. Oncol. 19 1160 1166 11181682 (Pubitemid 32176294)
17. F. Marre G. J. Sanderink G. de Sousa C. Gaillard M. Martinet R. Rahmani 1996 Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans Cancer Res. 56 1296 1302 8640817 1:CAS:528:DyaK28XhsFGntro%3D (Pubitemid 26080972)
18. S. M. Pathak N. Udupa 2010 Pre-clinical evidence of enhanced oral bioavailability of the P-glycoprotein substrate talinolol in combination with morin Biopharm. Drug Dispos. 31 202 214 20238375 1:CAS:528:DC%2BC3cXksV2mtr4%3D
19. Y. J. Piao J. S. Choi 2008 Effects of morin on the pharmacokinetics of nicardipine after oral and intravenous administration of nicardipine in rats J. Pharm. Pharmacol. 60 625 629 18416939 10.1211/jpp.60.5.0008 1:CAS:528: DC%2BD1cXltlemtrg%3D (Pubitemid 351589050)
20. J. Russo I. H. Russo 2000 Atlas and histologic classification of tumors of the rat mammary gland J. Mammary Gland Biol. Neoplasia 5 187 200 11149572 10.1023/A:1026443305758 1:STN:280:DC%2BD3M7jvVegtQ%3D%3D (Pubitemid 32045695)
21. M. Sandström L. E. Simonsen A. Freijs M. O. Karlsson 1999 The pharmacokinetics of epirubicin and docetaxel in combination in rats Cancer Chemother. Pharmacol. 44 469 474 10550567 10.1007/s002800051120 (Pubitemid 29501016)
22. S. C. Shin Y. J. Piao J. S. Choi 2008 Effects of morin on the bioavailability of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats In Vivo 22 391 395 18610753 1:CAS:528:DC%2BD1cXotlCksrw%3D
23. A. Sparreboom O. van Tellingen W. J. Nooijen J. H. Beijnen 1998 Preclinical pharmacokinetics of paclitaxel and docetaxel Anticancer Drugs 9 1 17 9491787 10.1097/00001813-199801000-00001 1:CAS:528:DyaK1cXotVOrug%3D%3D (Pubitemid 28088174)
24. J. H. Suh H. E. Kang I. S. Yoon S. H. Yang S. H. Kim H. J. Lee C. K. Shim M. G. Lee 2011 Cysteine effects on the pharmacokinetics of etoposide in protein-calorie malnutrition rats: increased gastrointestinal absorption by cysteine Xenobiotica 41 885 894 21623701 10.3109/00498254.2011.585186 1:CAS:528:DC%2BC3MXhtFKrtLfP
25. K. E. Thummel 2007 Gut instincts: CYP3A4 and intestinal drug metabolism J. Clin. Invest. 117 3173 3176 17975661 10.1172/JCI34007 1:CAS:528: DC%2BD2sXht12isr7E (Pubitemid 350096972)
26. R. Vaclavikova P. Soucek L. Svobodova P. Anzenbacher P. Simek F. P. Guengerich I. Gut 2004 Different in vitro metabolism of paclitaxel and docetaxel in humans, rats, pigs, and minipigs Drug Metab. Dispos. 32 666 674 15155559 10.1124/dmd.32.6.666 1:CAS:528:DC%2BD2cXktlOgt7w%3D (Pubitemid 38668160)
27. S. H. Yang J. H. Suh M. G. Lee 2010 Pharmacokinetic interaction between tamoxifen and ondansetron in rats: non-competitive (hepatic) and competitive (intestinal) inhibition of tamoxifen metabolism by ondansetron via CYP2D subfamily and 3A1/2 Cancer Chemother. Pharmacol. 65 407 418 19504095 10.1007/s00280-009-1043-4 1:CAS:528:DC%2BC3cXjt1ynug%3D%3D
28. S. Zhang M. E. Morris 2003 Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport J. Pharmacol. Exp. Ther. 304 1258 1267 12604704 10.1124/jpet.102.044412 1:CAS:528: DC%2BD3sXit1eisL0%3D (Pubitemid 36254439)